Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/1/05 → 1/31/11 |
A Randomized Open-label Study of 400 mg Versus 800 mg of Gleevac/Gilvac (imatinab mesylate) in patients with newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) using Molecular Endpoints
- McDonagh, Kevin (PI)